8-K current report · filed Aug 3, 2026

Indivior Pharmaceuticals, Inc. (INDV) 8-K Current Report: August 3, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2INDV overview

Short answer

Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 financial results for period ended June 30, 2026.

Indivior Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for period ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive earnings details

Item 7.01 · Regulation FD Disclosure

  • Presentation materials furnished as Exhibit 99.2 under Item 7.01 Regulation FD disclosure
  • Materials posted on Indivior’s website August 3, 2026
  • Investor-relevant details contained in Exhibit 99.2 and the company website

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $343M, up 14% YoY, led by SUBLOCADE revenue $253M, up 21%
  • Adjusted EBITDA $186M, up 111%, while GAAP net income reached $122M versus $18M
  • Raised FY2026 revenue guidance to $1.295B–$1.365B and adjusted EBITDA guidance to $700M–$740M
  • Repurchased 4.7M shares for $175M in Q2, bringing year-to-date repurchases to $300M
  • Proposed all-stock merger with Supernus expected in Q4, adding transaction-completion and integration risk to the outlook

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $343m, up 14%, with SUBLOCADE revenue $253m, up 21% on U.S. dispense growth of 18%
  • Net income $122m versus $18m, while adjusted EBITDA rose 111% to $186m and margin reached 54%
  • 2026 guidance raised: revenue $1,295m-$1,365m, SUBLOCADE $1,010m-$1,050m, adjusted EBITDA $700m-$740m
  • Cost discipline sustained: non-GAAP operating expenses capped at $450m, down 29% versus 2025 midpoint
  • Capital returned through $175m Q2 repurchases, while the proposed Supernus merger targets diversification and expected Q4’26 closing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Indivior Pharmaceuticals, Inc. 8-K filings

Get the next INDV 8-K as it lands

Follow INDV for push alerts, or ask the research agent what this filing means.